BIONDD®: Oral delivery of biologics from a small, easy-to-swallow capsule, in place of the injection.

Biograil · pre-clinical stage · Roskilde, Denmark

Still from Biograil's 2024 animation: the BIONDD capsule shown inside the stomach in a cut-away of the upper body

Biograil is a pre-clinical stage pharmaceutical company working to transform injectable medicines into convenient oral capsules.

BIONDD® is the platform behind it. A device sits inside a conventional capsule and delivers the drug into tissue after the capsule is swallowed, so biologics that today depend on a needle could be taken by mouth.

How BIONDD works

From capsule to tissue in four steps

Drawn from Biograil's own description of the mechanism. Scroll to follow the device.

Schematic, not to scale Schematic cut-away: the BIONDD capsule travels down the oesophagus, dissolves in the stomach, the device attaches to the stomach wall and releases the drug into the tissue, then passes through the GI tract. Source: biograil.com/the-technology
  1. SwallowedA conventional and small, easy-to-swallow capsule carries the device and the biologic.
  2. ReleasedThe capsule dissolves in the stomach and releases a device with a spring-loaded grabbing mechanism.
  3. AttachedThe device attaches to the stomach wall, releasing medication into the tissue for systemic distribution.
  4. PassedAfter drug delivery, the bio-compostable device passes through the GI tract.

One device, several classes of biologic

BIONDD is being developed as a platform for oral delivery of biologics, including peptides, antibodies and RNAs. Biograil works with pharma partners on the compounds that would benefit.

  • Peptides

    Named by Biograil as part of the platform scope for oral delivery.

    Platform scope
  • Antibodies

    Large molecules named by Biograil as part of the platform scope.

    Platform scope
  • RNAs

    Nucleic-acid therapeutics named by Biograil as part of the platform scope.

    Platform scope
Discuss your compound with Biograil

Financing

“Excellent to see such strong support from existing internal investors.” Karsten Lindhardt, CEO, on the EUR 20 million round, November 2026
Round
EUR 20 million
Investors
Verve Ventures, Megatrend Invest, HTGF via its HTGF Opportunity fund
Use of funds
Preparing Phase 1 clinical testing of BIONDD®: non-clinical GLP studies and a GMP manufacturing process
Next
A larger financing is expected in 2027

Work with Biograil

Pharma partners

Licensing and co-development of BIONDD® with your biologic. Talk to the team in Roskilde about your compound.

Start a partnering talk

Investors

Backed by Verve Ventures, Megatrend Invest and HTGF, with a larger round expected in 2027.

Investor information

Careers

Analytical Development & CMC role in Roskilde. Applications until 1 December 2026.

View the open role